These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29782326)

  • 21. Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia.
    Alafuzoff I; Adolfsson R; Bucht G; Winblad B
    J Neurol Sci; 1983; 60(3):465-72. PubMed ID: 6631444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease.
    Laske C; Stellos K; Kempter I; Stransky E; Maetzler W; Fleming I; Randriamboavonjy V
    Alzheimers Dement; 2015 May; 11(5):465-74. PubMed ID: 25200336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.
    Fania C; Arosio B; Capitanio D; Torretta E; Gussago C; Ferri E; Mari D; Gelfi C
    PLoS One; 2017; 12(6):e0179280. PubMed ID: 28628634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation.
    Ramos-Fernández E; Tajes M; Palomer E; Ill-Raga G; Bosch-Morató M; Guivernau B; Román-Dégano I; Eraso-Pichot A; Alcolea D; Fortea J; Nuñez L; Paez A; Alameda F; Fernández-Busquets X; Lleó A; Elosúa R; Boada M; Valverde MA; Muñoz FJ
    J Alzheimers Dis; 2014; 40(3):643-57. PubMed ID: 24503620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease.
    Yamamoto K; Shimada H; Koh H; Ataka S; Miki T
    Geriatr Gerontol Int; 2014 Jul; 14(3):716-23. PubMed ID: 24020590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.
    Johansson P; Almqvist EG; Bjerke M; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
    J Alzheimers Dis; 2017; 59(3):1017-1026. PubMed ID: 28697566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aβ1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease.
    Pérez-Grijalba V; Pesini P; Allué JA; Sarasa L; Montañés M; Lacosta AM; Casabona D; San-José I; Boada M; Tárraga L; Ruiz A; Sarasa M
    J Alzheimers Dis; 2015; 43(1):47-56. PubMed ID: 25061046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.
    Schirinzi T; Di Lazzaro G; Sancesario GM; Colona VL; Scaricamazza E; Mercuri NB; Martorana A; Sancesario G
    J Neural Transm (Vienna); 2017 Dec; 124(12):1621-1625. PubMed ID: 28866757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.
    Sun YX; Minthon L; Wallmark A; Warkentin S; Blennow K; Janciauskiene S
    Dement Geriatr Cogn Disord; 2003; 16(3):136-44. PubMed ID: 12826739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content.
    Kontush A; Donarski N; Beisiegel U
    Free Radic Res; 2001 Nov; 35(5):507-17. PubMed ID: 11767409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender differences in albumin and ascorbic acid in the vitreous antioxidant system.
    Schwab C; Paar M; Fengler VH; Ivastinovic D; Haas A; Seidel G; Glatz W; Malle EM; Weger M; Velikay-Parel M; Faustmann G; Wedrich A; Reibnegger G; Winklhofer-Roob B; Oettl K
    Free Radic Biol Med; 2020 Jan; 146():257-263. PubMed ID: 31705958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer's disease and multi-infarct dementia.
    Elovaara I; Palo J; Erkinjuntti T; Sulkava R
    Eur Neurol; 1987; 26(4):229-34. PubMed ID: 3595662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Lundh T; Minthon L; Londos E
    Dement Geriatr Cogn Disord; 2008; 25(6):508-15. PubMed ID: 18463412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.